VideoPsychedelicsTrade To Black

CEO Nyquvest Explains Partnership Between Numinus And MAPS

By Shadd Dales On Jun 17, 2023

We’re back with another TDR Psychedelic Exclusive. In this latest, we connect again with the CEO of Numinus Wellness (TSX: NUMI), Payton Nyquvest. In case you missed it, he was last on our show at the end of May, discussing some of the initiatives planned to help better position Numinus. This time, Nyquvest is here to discuss their latest news involving a partnership between Numinus and MAPS.

The upcoming MAPS conference about to take place in Denver is generating a lot of interesting news and rumors. Many companies in the psychedelics industry will be participating, and Numinus will be one of them. Nyquvest shares what is going to be Numinus’ main objectives during the conference, and what they hope to achieve with the many practitioners who will be attending.

Visitors and investors can anticipate a range of exciting events and discussions at the MAPS conference, but what is Numinus anticipating? Nyquvest shares some thoughts, and why he believes psychedelics saved his life.

Delving into the partnership between Numinus Wellness and MAPS, Nyquvest explains that it aims to support psychedelic experiential opportunities for practitioners that will be part of a Phase 1 clinical study. During our conversation, we asked Payton Nyquvest about Numinus’ ability to administer MDMA assisted therapy if it receives FDA approval before the announced trial with MAPS is complete. We also discussed whether this partnership marks a new progressive chapter in deepening ties and building a stronger relationship with MAPS. Most importantly, we asked whether these partnerships are exclusive.

That’s not all the news from Numinus, however, that Nyquvest has to share. There’s a new Chief Financial Officer who has been hired, and this development dovetails with a very exciting possibility of a NASDAQ that might be coming this fall. Find out why this CFO hire is so important to the company in the face of becoming publicly traded.

Listen in to get the latest.

__________

* In accordance with an executed agreement between The Dales Report and Numinus Wellness, The Dales Report is engaged with the aforementioned on a 12-month contract for $10,000 per month, with the purpose of publicly disseminating information pertaining to Numinus Wellness via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for The Dales Report services involves the receipt of a predefined monetary consideration, which may, on certain occasions, encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations. Please refer to the “Disclosures” section below, which is to be interpreted in conjunction with this disclaimer.

psychedelic Psychedelic company psychedelics

Shadd Dales is the Founder and President of The Dales Report and has an extensive background in the business media industry.

His work translates into over 15 years in mainstream media that included roles with BNN Bloomberg, CTV Properties and the iHeart Radio Network.

Shadd is considered one of the leading on air talents in both the cannabis and psychedelic space and has interviewed some of the most notable CEO names in the industry.

Shadd’s vision is to establish a content platform that is equivalent to a mainstream broadcast produced in a format that is relevant for today’s investor.